Evidence map›Paper›PMID 30341700›Full record

ReviewHeart failure reviews2019

Chronic heart failure: a disease of the brain.

Ram B Singh, Krasimira Hristova, Jan Fedacko, Galal El-Kilany, Germaine Cornelissen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. The clinical value of circadian biofeedback in chronic heart failure.European heart journal. Digital health · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Sympathetic and parasympathetic central autonomic networks.Imaging neuroscience (Cambridge, Mass.) · 2024
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 4 countries.

Ram B SinghThe Tsim Tsoum Institute, Krakow, Poland. rbs@tsimtsoum.net.ORCID 0000-0002-4922-0405
Krasimira HristovaNational Heart Hospital, Sofia, Bulgaria.
Jan FedackoFaculty of Medicine, PJ Safaric University, Kosice, Slovakia.
Galal El-KilanyGulf Medical College, Ajman, UAE.
Germaine CornelissenHalberg Chronobiology Center, University of Minnesota Medical School, Minneapolis, USA.
Abilities In Motion · USGulf Medical University · AENational Heart Hospital · BGUniversity of Minnesota Medical Center · USUniversity of Pavol Jozef Šafárik · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The underlying mechanism for clinical and biochemical manifestations of chronic heart failure (HF) may be due in part to neurohumoral adaptations, such as activation of the renin-angiotensin-aldosterone and sympathetic nervous systems in the periphery and the brain. Internet search and discussion with colleagues are the methods for this study. Since chronic HF is associated with autonomic imbalance with increased sympathetic nerve activity and a withdrawal of parasympathetic activity, it may be considered a brain disease. This phenomenon may be the result of an increased systemic and cerebral angiotensin II signaling because plasma angiotensin II is increased in humans and animals with chronic HF. The increase in angiotensin II signaling enhances sympathetic nerve activity through actions on both central and peripheral sites during chronic HF. Activation of angiotensin II signaling in different brain sites such as the paraventricular nucleus (PVN), rostral ventrolateral medulla (RVLM), and area postrema (AP) may increase the release of norepinephrine, oxidative stress, and inflammation leading to increased cardiac contractility. It is possible that blocking angiotensin II type 1 receptors decreases sympathetic nerve activity and cardiac sympathetic afferent reflex when therapy is administered to the PVN. The administration of an angiotensin receptor blocker by injection into the AP activates the sympatho-inhibitory baroreflex indicating that receptor blockers act by increasing parasympathetic activity. In chronic HF, in peripheral regions, angiotensin II elevates both norepinephrine release and synthesis and inhibits norepinephrine uptake at nerve endings, which may contribute to the increase in sympathetic nerve activity. Increased circulating angiotensin II during chronic HF may enhance the sympatho-excitatory chemoreflex and inhibit the sympatho-inhibitory baroreflex resulting in worsening of HF. Increased circulating angiotensin II signaling can directly act on the central nervous system via the subfornical organ and the AP to increase sympathetic outflow resulting in to neurohumoral dysfunction, resulting in to heart failure.

Indexed as

Angiotensin IIAngiotensin Receptor AntagonistsAnimalsBaroreflexBrainCardiomegalyChronic DiseaseHeartHeart FailureHumansInflammationNatriuretic Peptide, BrainNeuroimmunomodulationNorepinephrineOxidative StressParaventricular Hypothalamic NucleusAngiotensin IIAngiotensin Receptor AntagonistsNatriuretic Peptide, BrainNorepinephrinePeptide Fragmentspro-brain natriuretic peptide (1-76)Brain-heart interactionsCardiac failureHypertrophy of heartNeurohumoral dysfunction

Identifiers

PMID30341700
OpenAlexW2897685771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.